Use of bisphosphonates and reduced risk of colorectal cancer.

  • Rennert G
  • Pinchev M
  • Rennert H
 et al. 
  • 15


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and were recently reported to be associated with a reduced risk of breast cancer, possibly acting through the mevalonate pathway, but their association with risk of other cancers is unknown.

PATIENTS AND METHODS: The Molecular Epidemiology of Colorectal Cancer study is a population-based, case-control study in northern Israel of patients with colorectal cancer and age-, sex-, clinic-, and ethnic group-matched controls. Long-term use of bisphosphonates before diagnosis was assessed in a subset of 933 pairs of postmenopausal female patients and controls, enrolled in Clalit Health Services, using computerized pharmacy records.

RESULTS: The use of bisphosphonates for more than 1 year before diagnosis, but not for less than 1 year, was associated with a significantly reduced relative risk (RR) of colorectal cancer (RR, 0.50; 95% CI, 0.35 to 0.71). This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones (RR, 0.41; 95% CI, 0.25 to 0.67). Concomitant use of bisphosphonates and statins did not further reduce the risk.

CONCLUSION: The use of oral bisphosphonates for more than 1 year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.

Author-supplied keywords

  • Aged
  • Bone Density Conservation Agents
  • Bone Density Conservation Agents: therapeutic use
  • Bone Neoplasms
  • Bone Neoplasms: drug therapy
  • Bone Neoplasms: epidemiology
  • Bone Neoplasms: secondary
  • Case-Control Studies
  • Colorectal Neoplasms
  • Colorectal Neoplasms: drug therapy
  • Colorectal Neoplasms: epidemiology
  • Colorectal Neoplasms: pathology
  • Diphosphonates
  • Diphosphonates: therapeutic use
  • Female
  • Humans
  • Israel
  • Israel: epidemiology
  • Male
  • Menopause
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Gad Rennert

  • Mila Pinchev

  • Hedy S Rennert

  • Stephen B Gruber

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free